Interleukin‐6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors

Interleukin‐6 (IL‐6) may play a pathological role in rheumatoid arthritis (RA) and periodontitis. Although the efficacy of medication with IL‐6 receptor inhibitor, tocilizumab (TCZ), has been demonstrated in the treatment of RA, very little is known about whether TCZ therapy affects periodontitis. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Tetsuo, Ito, Satoshi, Kobayashi, Daisuke, Kojima, Anri, Shimada, Atsushi, Narita, Ichiei, Murasawa, Akira, Nakazono, Kiyoshi, Yoshie, Hiromasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839195/
https://www.ncbi.nlm.nih.gov/pubmed/29744142
http://dx.doi.org/10.1002/cre2.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839195/
https://www.ncbi.nlm.nih.gov/pubmed/29744142
http://dx.doi.org/10.1002/cre2.11

Ejemplares similares